2020
DOI: 10.3390/ijms21020683
|View full text |Cite
|
Sign up to set email alerts
|

Topical Therapy with Antisense Tumor Necrosis Factor Alpha Using Novel β-Glucan-Based Drug Delivery System Ameliorates Intestinal Inflammation

Abstract: Anti-tumor necrosis factor alpha (TNF-α) antibodies are effective in patients with inflammatory bowel disease (IBD). However, the effect is not optimal because a sufficient concentration of antibodies cannot be maintained at the site of inflammation. Thus, a macromolecular complex was developed with schizophyllan (SPG) and antisense oligonucleotides. In the present study, an SPG-antisense TNF-α complex was prepared, and its therapeutic efficacy was examined using a dextran sodium sulfate (DSS)-induced colitis … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
6
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 17 publications
(6 citation statements)
references
References 40 publications
0
6
0
Order By: Relevance
“…SPG-ASO is an enema containing ASO against TNF-α complexed with the polysaccharide schizophyllan, which is a β-(1–3) glucan [ 117 ]. The complexion resulted in a stable ASO formulation that was targeted to cells expressing the Dectin-1 receptor.…”
Section: Preclinical Studies On Local Tnf-α Inhibitionmentioning
confidence: 99%
“…SPG-ASO is an enema containing ASO against TNF-α complexed with the polysaccharide schizophyllan, which is a β-(1–3) glucan [ 117 ]. The complexion resulted in a stable ASO formulation that was targeted to cells expressing the Dectin-1 receptor.…”
Section: Preclinical Studies On Local Tnf-α Inhibitionmentioning
confidence: 99%
“…Tumor necrosis factor-alpha (TNFα) is a critical cytokine involved in various autoimmune diseases as it plays a widespread role in the establishment and maintenance of inflammation. 49 TNFα plays a pathogenic role in many inflammatory ailments by acting as a vital controller of inflammatory pathways. 50 We selected the well-known inhibitor of TNFα namely 6,7-dimethyl-3-((methyl -(2-(methyl-((1-(3-(trifluoromethyl) phenyl)indol-3-yl) methyl) amino) ethyl) amino) methyl)chromen-4-one (AC1NS1JP) as a positive control.…”
Section: Discussionmentioning
confidence: 99%
“…of TNF-α at the site of inflammation thereby increased therapeutic efficacy. 130 Both, the time to loss of crust and time to crusting of lesions were shorter in subjects treated with nanoformulation than with the commercial cream. 133 In a study, evaluated ammonium glycyrrhizinate loaded ethosomal suspension (size 100-350 nm) for their potential topical application in human volunteers applied for 48 hr.…”
Section: Latest Nanotechniques Under Development For Topical Deliverymentioning
confidence: 92%